ABL Awarded 3-Year Program Extension as the Biologics Production Facility for NHLBI’s SMARTT Program

ABL Awarded 3-Year Program Extension as the Biologics Production Facility for NHLBI’s SMARTT Program

  • March 11, 2016

Rockville, MD—March 11, 2016 –- ABL is pleased to announce the National Heart, Lung and Blood Institute has awarded a three year extension for the Science Moving towArds Research Translation and Therapy (SMARTT) program. ABL has served as the SMARTT GMP (good manufacturing practice) Biologics Production Facility since 2010 with the goal to support translational research of promising, protein-based investigator-initiated treatments for heart, lung and blood diseases. The Biologics Production Facility provides development and biomanufacturing services for the SMARTT program to help advance therapies from bench to clinic.

The follow-on contract will extend the program to a total of eight years in order to support on-going activities, launch new projects meeting funding criteria, and to provide a dependable biologics manufacturing option for other NHLBI translational programs to leverage.

Please contact ABL by email or call 301-881-5600 if interested in discussing your biologics manufacturing needs. For investigators interested in applying for NHLBI SMARTT funds, you can submit an application online at https://www.nhlbismartt.org/.

About ABL

ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including biopharmaceutical companies, government and academic entities. Notable cGMP manufacturing services for protein and virus products include process and assay development,  Phase I/II cGMP biologics manufacturing of bulk drug substance, cGMP aseptic fill and finish of drug product, and QC analytics.  ABL also maintains immunological and molecular laboratories to support preclinical and GCLP clinical sample processing and testing. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.